We are seeking a partner to conduct POC preclinical work followed by a Phase I/II trial in order to adapt our immunotherapy technology platform for the treatment of SARS-CoV-2 infection.
Both trials will target, in addition to the spike protein already targeted by antibody vaccines, several conservative proteins of the ORF1ab region of SARS-CoV-2, with the primarily endpoint of generating long lasting memory T-cell immune response against SARS-CoV-2.
For information on the importance of targeting the ORF1ab region and the significance of T-cell immune response please read this publication:
"Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patients" available HERE.
Genetic Immunity first proposed targeting the ORF1ab region of SARS-CoV-2 in June of 2020. If your organization has an interest in exploring this trial please contact us.
Clinical Trials PROPOSED WITH COVIDERM
Proposed Trial Title Status
Preclinical POC study to demonstrate SARS-CoV-2 specific immune response using our proprietary antigen specific pDNA construct.
A Phase I/II, randomized, double-blind placebo controlled study to evaluate the safety, tolerability and Immunogenicity of Coviderm T-cell Immune therapy for the treatment of SARS-CoV-2 infection